VCG
HZNP

Vantage Consulting Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Vantage Consulting Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12
Closed -$1K – 1855
2020
Q4 		$1K Buy
+12
New +$892 ﹤0.01% 1859

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vantage Consulting Group's HZNP Position: Q1 2021 in Review

Vantage Consulting Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 12 shares — an estimated $1K sold.

Vantage Consulting Group first reported a position in HZNP in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

  • Vantage Consulting Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 12 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $1K.
  • Vantage Consulting Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1K in Q4 2020.
  • 516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.